From Phase 1b to Phase 2: What the Trials Have Measured

Before the details

Retatrutide is an investigational drug — not approved, not available by prescription, and still in Phase 3 trials. This page covers the published clinical and laboratory research: what doses were studied, in which types of patients, what was measured, and what numbers came back. All claims below are drawn from peer-reviewed publications and are cited in brackets. The underlying retatrutide mechanism of action page explains the pharmacology in more depth; this page focuses on the trial evidence. The compound's key property is that it activates three receptors simultaneously — GIP, GLP-1, and glucagon — and that pharmacological triple-punch is what gives the Phase 2 numbers their unusual magnitude. Understanding what those numbers mean, and what questions remain, is what this research page is for.

Phase 1b — first-in-human pharmacokinetics and early efficacy

The foundational human data came from a 12-week Phase 1b multiple-ascending-dose study in 72 adults with type 2 diabetes (HbA1c 7.0-10.5%) ^[4]. The objectives were tolerability, pharmacokinetics (how the drug behaves in the body), and early efficacy signals. Doses ranging from 0.5 mg to a 3/6/9/12 mg escalation schedule were administered by subcutaneous injection once weekly.

The key pharmacokinetic finding: retatrutide has a half-life (the time for blood concentration to fall by half) of approximately 6 days, which supports a once-weekly injection schedule ^[4]. At the highest-dose group, placebo-adjusted weight loss reached -8.96 kg (90% CI -11.16 to -6.75) over just 12 weeks — a signal strong enough to justify proceeding immediately to Phase 2. Daily glucose fell by -2.8 mmol/L at 3 mg. Treatment-emergent adverse events were reported in 63% of participants, mostly gastrointestinal; the safety profile was described as acceptable.

A 2024 commentary on retatrutide's development trajectory noted that Phase 1 proof-of-concept established dose-escalation feasibility and tolerability as the foundation for the Phase 2 trials that would eventually document up to 24% body weight reduction and nearly 20 cm waist circumference reduction ^[9].

Phase 2 in obesity — the 48-week headline trial

The pivotal Phase 2 obesity trial (Jastreboff AM, et al., New England Journal of Medicine, 2023) enrolled 338 adults with obesity or overweight with a comorbidity, without type 2 diabetes ^[1]. Participants received once-weekly subcutaneous retatrutide at 1, 4, 8, or 12 mg, or placebo, for 48 weeks.

Retatrutide results from this trial:

• Mean body-weight change at 48 weeks: -24.2% at 12 mg vs -2.1% with placebo ^[1]
• Waist circumference reduction: approximately 19.4 cm at 12 mg ^[1]
• Dose-dependent effect: -8.7% (1 mg), -17.3% (4 mg), -22.8% (8 mg), -24.2% (12 mg) ^[1]
• Gastrointestinal adverse events (nausea, diarrhea, vomiting, constipation): dose-related; nausea in up to 45% at 12 mg ^[1]
• Dose-dependent heart-rate increase: peaking around 24 weeks at approximately 5-7 bpm above baseline at highest doses ^[1]
• Discontinuation rate: 18% at 12 mg, primarily due to GI adverse events ^[1]

A 2025 review in Biomolecules synthesized this and the Phase 1/2 data, characterizing the up-to ~24% weight loss as "a step-change versus prior incretin therapies" ^[6]. A 2024 review in Cell described the triple-agonist mechanism as the pharmacological basis for weight losses that rival bariatric surgery in magnitude ^[10].

Phase 2 in type 2 diabetes

A parallel 36-week Phase 2 randomized controlled trial (Rosenstock J, et al., Lancet, 2023) enrolled 281 adults with type 2 diabetes ^[2]. Retatrutide was studied across a 0.5-12 mg once-weekly dose range with stepwise escalation.

At 24 weeks, the 12 mg arm produced HbA1c reduction of -2.02% versus -0.01% with placebo — a clinically meaningful glycemic improvement ^[2]. At 36 weeks, body weight decreased by -16.94% with 12 mg versus -3.00% with placebo. Mild-to-moderate GI adverse events occurred in approximately 35% of participants; no severe hypoglycemia and no deaths were reported. Participants on background insulin required insulin dose reductions.

The lipid and metabolic profile has been examined in a 2026 substudy (Pearson MJ, et al., Journal of Clinical Endocrinology & Metabolism): higher retatrutide doses were associated with reductions in triglycerides and insulin-resistance biomarkers, with changes in fatty-acid oxidation patterns mediating 23.2% of the weight-reduction response in non-type-2-diabetes participants ^[13].

Phase 2 substudy in MASLD — liver fat reduction

MASLD (metabolic dysfunction-associated steatotic liver disease — the current term for what was formerly called non-alcoholic fatty liver disease) is an indication where retatrutide's triple mechanism may have particular relevance, because glucagon-receptor activation drives hepatic lipid metabolism directly.

A 48-week Phase 2 substudy (Sanyal AJ, et al., Nature Medicine, 2024) enrolled 98 participants with obesity or overweight and MASLD — defined as ≥10% liver fat by MRI-PDFF — without type 2 diabetes ^[5]. Results at 24 weeks: relative liver-fat change of -82.4% at the 12 mg dose versus +0.3% with placebo; 86% of participants at 12 mg reached normal liver-fat content (below 5% by MRI-PDFF) ^[5]. Those reductions were sustained to 48 weeks, reaching -86.0% at 12 mg. The 2026 mechanistic review in Frontiers in Medicine described the hepatic lipid metabolism, anti-inflammatory, and fibrosis-modulating pathways through which GLP-1/GIP/glucagon triple agonism achieves these liver effects ^[15].

Structural biology — cryo-EM binding data

A 2024 paper in Cell Discovery (Li W, et al.) resolved the molecular structure of retatrutide bound to all three target receptors using cryo-electron microscopy ^[3]. The structures were resolved at 2.68, 3.26, and 2.84 angstroms resolution for GLP-1R, GIPR, and GCGR respectively.

Key structural findings: retatrutide engages all three receptors; it shows approximately 8.9-fold higher potency at GIPR compared with native GIP, but 0.3-fold and 0.4-fold potency at GCGR and GLP-1R respectively, relative to their native hormones ^[3]. This tuned relative potency — strong GIP agonism, moderate GLP-1 and glucagon agonism — is the engineered pharmacological signature that produces the compound's weight and metabolic profile. The extracellular loop 1 (ECL1) of the receptor adopts a rigid alpha-helix in GLP-1R and GCGR when bound to retatrutide, but a flexible loop in GIPR — a structural difference that may explain the differential potency ^[3].

A 2025 study (Wen Y, et al., Diabetes, Obesity & Metabolism) examined downstream lipid effects: reductions in ANGPTL3/8 concentrations — proteins that regulate circulating triglycerides — were observed at 8 and 12 mg in both obesity and type 2 diabetes populations, with GCGR agonism mechanistically implicated ^[14]. Reductions paralleled decreases in triglycerides and LDL-C.

Retatrutide dosage — research context

Doses studied in clinical trials: 1, 4, 8, and 12 mg subcutaneous once weekly in the Phase 2 obesity trial ^[1]; 0.5-12 mg with stepwise escalation in Phase 2 type 2 diabetes ^[2]; 0.5, 1.5, 3, and 3/6/9/12 mg escalation in Phase 1b ^[4]. These are study-design facts, not dosing guidance. Retatrutide is not available as a prescription product and has no approved dosing schedule.

The pharmacokinetic parameters from Phase 1b established the basis for once-weekly administration: approximately 6-day half-life in human plasma ^[4]. Administration was by subcutaneous injection in all completed trials.

How to reconstitute retatrutide: There is no approved or standardized reconstitution protocol. Retatrutide in clinical trials is supplied as a sterile, pre-formulated single-use injection pen or vial by the trial sponsor under GMP conditions. There is no equivalent standard for research-labeled gray-market material, and any reconstitution guide circulating online refers to an unverified product. This site does not provide reconstitution instructions.

Retatrutide cost — current status

Retatrutide has no commercial price because it is not commercially available. It is an investigational compound that has not received FDA approval or any other marketing authorization. The cost question is premature.

Gray-market research-labeled material is available through unregulated channels, but no price for such material is cited here. The FDA issued over 50 warning letters to sellers of research-labeled retatrutide in 2025 ^[7]. The relevant economic question — what an approved product might cost relative to other drugs in its class — cannot be answered until the compound is approved, if it is.